Literature DB >> 17670280

Early and intensive continuous veno-venous hemofiltration for acute renal failure after cardiac surgery.

Vinayak Bapat1, Michael Sabetai, Jamers Roxburgh, Christopher Young, Graham Venn.   

Abstract

Various forms of renal replacement therapies are available to treat acute renal failure (ARF) after cardiac surgery. The objective of this study was to assess the incidence of ARF developing postoperatively necessitating continuous veno-venous hemofiltration (CVVH) in adult patients requiring cardiopulmonary bypass (CPB), to determine the factors which influence the outcome in these patients and to assess the outcome following the use of early and intensive CVVH. During the study period, i.e. August 2000 to July 2002, 2355 adult patients underwent surgery under CPB, of whom 159 (6.7%) developed renal failure (creatinine >200 micromol/l) and 116 (5%) needed CVVH. Patients excluded were those who died within 24 h and those who underwent coronary artery bypass grafting without utilising CPB, thoracoabdominal aneurysm operations and pericardial surgery. Average age, Parsonnet score and Euroscore in the study population were 69.9 years, 21 and 7.70, respectively. Of the 116, 45 died in the intensive care unit (38.8% mortality). Relatively more non-survivors suffered from diabetes and preoperative renal dysfunction (P<0.05). Adverse outcome was also more likely if patient suffered from postoperative cardiac failure or had gastrointestinal complications or had more than two organ systems failing (P<0.05). Mortality was 100% if hepatic failure ensued.

Entities:  

Year:  2004        PMID: 17670280     DOI: 10.1016/j.icvts.2004.03.002

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  1 in total

1.  New, goal-directed approach to renal replacement therapy improves acute kidney injury treatment after cardiac surgery.

Authors:  Jiarui Xu; Xiaoqiang Ding; Yi Fang; Bo Shen; Zhonghua Liu; Jianzhou Zou; Lan Liu; Chunsheng Wang; Jie Teng
Journal:  J Cardiothorac Surg       Date:  2014-06-18       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.